{"id":"exemestane-tablets","safety":{"commonSideEffects":[{"rate":"36","effect":"Hot flashes"},{"rate":"28","effect":"Arthralgia/joint pain"},{"rate":"13","effect":"Fatigue"},{"rate":"9","effect":"Nausea"},{"rate":"8","effect":"Headache"},{"rate":null,"effect":"Osteoporosis/bone loss"},{"rate":null,"effect":"Vaginal dryness"}]},"_chembl":{"chemblId":"CHEMBL1200374","moleculeType":"Small molecule","molecularWeight":"296.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Exemestane irreversibly inhibits the aromatase enzyme, which catalyzes the final step of estrogen biosynthesis in peripheral tissues. By reducing circulating estrogen levels, it deprives estrogen-dependent breast cancer cells of growth signals. This mechanism is particularly effective in postmenopausal women where peripheral aromatization is the primary source of estrogen.","oneSentence":"Exemestane is a steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:29.861Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer in postmenopausal women (adjuvant and extended therapy)"},{"name":"Advanced or metastatic breast cancer in postmenopausal women"}]},"trialDetails":[{"nctId":"NCT06492616","phase":"PHASE3","title":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2024-09-27","conditions":"Breast Cancer","enrollment":4220},{"nctId":"NCT06428396","phase":"PHASE2","title":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-27","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT04572295","phase":"PHASE1","title":"A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Co., Ltd.","startDate":"2020-10-09","conditions":"Breast Neoplasms","enrollment":51},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT06127979","phase":"NA","title":"A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-11-06","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT06105632","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-01-09","conditions":"Advanced or Metastatic Breast Cancer","enrollment":333},{"nctId":"NCT07024173","phase":"PHASE3","title":"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2025-07-23","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":240},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":"Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":90},{"nctId":"NCT04584853","phase":"PHASE3","title":"PreOperative Endocrine Therapy for Individualised Care With Abemaciclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-23","conditions":"Breast Cancer Female","enrollment":123},{"nctId":"NCT04906395","phase":"PHASE3","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05645536","phase":"PHASE3","title":"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study","status":"ENROLLING_BY_INVITATION","sponsor":"Tolmar Inc.","startDate":"2022-12-28","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT07062965","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-05","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT06369285","phase":"PHASE2","title":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Puma Biotechnology, Inc.","startDate":"2024-11-19","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":150},{"nctId":"NCT03079011","phase":"PHASE3","title":"PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-22","conditions":"Metastatic Breast Cancer","enrollment":1017},{"nctId":"NCT06680921","phase":"PHASE3","title":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2024-11-14","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":460},{"nctId":"NCT02007512","phase":"PHASE2","title":"Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-12-16","conditions":"Breast Cancer","enrollment":247},{"nctId":"NCT05872347","phase":"PHASE2","title":"Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-09-19","conditions":"Breast Cancer Brain Metastases","enrollment":52},{"nctId":"NCT04300790","phase":"PHASE2","title":"Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-23","conditions":"Breast Cancer","enrollment":69},{"nctId":"NCT02123823","phase":"PHASE1","title":"BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-05-15","conditions":"Neoplasms","enrollment":164},{"nctId":"NCT03820830","phase":"PHASE3","title":"Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-08-27","conditions":"Breast Cancer Recurrent","enrollment":405},{"nctId":"NCT03659136","phase":"PHASE2","title":"The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-11-28","conditions":"Breast Neoplasms","enrollment":103},{"nctId":"NCT04985266","phase":"PHASE2","title":"A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2022-03-30","conditions":"ER+ Breast Cancer, HER2-negative Breast Cancer","enrollment":1100},{"nctId":"NCT06656624","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-13","conditions":"Advanced Breast Cancer","enrollment":190},{"nctId":"NCT02188745","phase":"PHASE2","title":"ER Reactivation Therapy for Breast Cancer","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2016-03-11","conditions":"Metastatic Breast Cancer","enrollment":19},{"nctId":"NCT03361800","phase":"EARLY_PHASE1","title":"Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC","status":"TERMINATED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-11-28","conditions":"Breast Cancer, Invasive Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer","enrollment":5},{"nctId":"NCT03308201","phase":"PHASE1","title":"Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","startDate":"2017-10-16","conditions":"Breast Cancer","enrollment":55},{"nctId":"NCT04460807","phase":"PHASE3","title":"Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer","status":"TERMINATED","sponsor":"Ente Ospedaliero Ospedali Galliera","startDate":"2020-02-13","conditions":"Ovarian Cancer","enrollment":23},{"nctId":"NCT06235931","phase":"NA","title":"A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2024-02-01","conditions":"Breast Neoplasms","enrollment":34},{"nctId":"NCT03312738","phase":"PHASE2","title":"A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-15","conditions":"Advanced Breast Cancer","enrollment":159},{"nctId":"NCT02258451","phase":"PHASE2","title":"Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-04","conditions":"Breast Neoplasms","enrollment":283},{"nctId":"NCT00083174","phase":"PHASE3","title":"Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2004-12-03","conditions":"Breast Cancer","enrollment":4560},{"nctId":"NCT03555877","phase":"PHASE2","title":"Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2018-03-15","conditions":"Breast Cancer Metastatic","enrollment":56},{"nctId":"NCT05890287","phase":"NA","title":"A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-16","conditions":"HR Positive HER2 Negative Advanced Breast Cancer","enrollment":60},{"nctId":"NCT02666105","phase":"PHASE2","title":"Exemestane in Post-Menopausal Women With NSCLC","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-09-27","conditions":"Non-Small Cell Lung Cancer","enrollment":6},{"nctId":"NCT01698918","phase":"PHASE2","title":"Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-07","conditions":"Hormone Receptor Positive Breast Cancer","enrollment":202},{"nctId":"NCT02894398","phase":"PHASE2","title":"Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2016-09-06","conditions":"Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","enrollment":388},{"nctId":"NCT02049957","phase":"PHASE2","title":"Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Calithera Biosciences, Inc","startDate":"2014-02-13","conditions":"Breast Cancer","enrollment":118},{"nctId":"NCT00828854","phase":"PHASE2","title":"Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2008-10-01","conditions":"ER+ Breast Cancer","enrollment":27},{"nctId":"NCT00676663","phase":"PHASE2","title":"Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2008-06-13","conditions":"Breast Cancer, Estrogen Receptor-Positive Breast Cancer, Breast Cancer, Estrogen Receptor-Positive","enrollment":130},{"nctId":"NCT02482753","phase":"PHASE3","title":"Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2015-07","conditions":"Breast Cancer","enrollment":365},{"nctId":"NCT02213042","phase":"PHASE2","title":"Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-10-24","conditions":"Neoplasms, Breast","enrollment":42},{"nctId":"NCT03078751","phase":"PHASE2","title":"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-20","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT02732119","phase":"PHASE1, PHASE2","title":"Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-14","conditions":"Breast Cancer","enrollment":104},{"nctId":"NCT04852081","phase":"","title":"Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2021-01-01","conditions":"Breast Cancer Stage IV","enrollment":1000},{"nctId":"NCT01857193","phase":"PHASE1","title":"Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09-06","conditions":"Breast Cancer","enrollment":132},{"nctId":"NCT01231659","phase":"PHASE2","title":"Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08-09","conditions":"Postmenopausal Women, Locally Advanced Metastatic Breast Cancer, Metastatic Breast Cancer","enrollment":72},{"nctId":"NCT01783444","phase":"PHASE2","title":"A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-26","conditions":"Breast Cancer","enrollment":309},{"nctId":"NCT03125746","phase":"PHASE1","title":"A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors","status":"UNKNOWN","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2017-06-12","conditions":"Advanced Breast Cancer","enrollment":72},{"nctId":"NCT02392611","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-03-16","conditions":"Solid Tumors and Lymphomas","enrollment":33},{"nctId":"NCT04666805","phase":"","title":"Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast","status":"UNKNOWN","sponsor":"First Hospital of China Medical University","startDate":"2020-07-01","conditions":"Breast Cancer","enrollment":1354},{"nctId":"NCT02511639","phase":"PHASE3","title":"Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2014-07-30","conditions":"Breast Cancer Metastatic","enrollment":110},{"nctId":"NCT04619914","phase":"NA","title":"the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women","status":"COMPLETED","sponsor":"Laylay Mohammed Khalleefah Alhibshi","startDate":"2019-03-01","conditions":"Endometrial Thickness, Pregnancy Rate","enrollment":160},{"nctId":"NCT01627067","phase":"PHASE2","title":"Exemestane-RAD001-Metformin","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-09","conditions":"Breast Cancer","enrollment":23},{"nctId":"NCT03176238","phase":"PHASE3","title":"Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-29","conditions":"Post Menopausal Breast Cancer","enrollment":235},{"nctId":"NCT01963481","phase":"PHASE2","title":"Exemestane and Cyclophosphamide for Metastatic Breast Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2013-09","conditions":"Metastatic Beast Cancer","enrollment":23},{"nctId":"NCT03024580","phase":"PHASE2","title":"A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancer, Brazil","startDate":"2017-03-06","conditions":"Breast Neoplasm","enrollment":20},{"nctId":"NCT02983604","phase":"PHASE1, PHASE2","title":"GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2017-01-10","conditions":"Advanced Estrogen Receptor Positive HER2- Breast Cancer","enrollment":14},{"nctId":"NCT01743560","phase":"PHASE4","title":"An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01-31","conditions":"Oestrogen Receptor Positive Advanced Breast Cancer","enrollment":52},{"nctId":"NCT01760980","phase":"PHASE1","title":"Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects","status":"WITHDRAWN","sponsor":"Actavis Inc.","startDate":"2012-11","conditions":"Healthy","enrollment":""},{"nctId":"NCT01597193","phase":"PHASE1","title":"Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-04-30","conditions":"Breast Cancer","enrollment":101},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT01381874","phase":"PHASE2","title":"A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-08-24","conditions":"Metastatic ER+ Her2- Breast Cancer, Postmenopausal","enrollment":297},{"nctId":"NCT01605396","phase":"PHASE2","title":"A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-04","conditions":"Breast Neoplasms","enrollment":80},{"nctId":"NCT03137368","phase":"PHASE3","title":"A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2018-08-09","conditions":"CYP2D6 Polymorphism","enrollment":300},{"nctId":"NCT02689921","phase":"PHASE2","title":"NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer","status":"UNKNOWN","sponsor":"Midwestern Regional Medical Center","startDate":"2016-04","conditions":"Breast Neoplasms","enrollment":7},{"nctId":"NCT03081234","phase":"PHASE3","title":"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2018-03-31","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT01331434","phase":"NA","title":"Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2004-10","conditions":"Breast Cancer","enrollment":47},{"nctId":"NCT01331447","phase":"NA","title":"Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2004-05","conditions":"Breast Cancer","enrollment":12},{"nctId":"NCT01331421","phase":"NA","title":"Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2004-07","conditions":"Breast Cancer","enrollment":48},{"nctId":"NCT02248571","phase":"PHASE4","title":"Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2014-08","conditions":"Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast","enrollment":85},{"nctId":"NCT00863655","phase":"PHASE3","title":"Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06-03","conditions":"Breast Cancer","enrollment":724},{"nctId":"NCT02467686","phase":"PHASE4","title":"Breast Cancer, Sexuality and Black Cohosh","status":"UNKNOWN","sponsor":"Irmandade da Santa Casa de Misericordia de Sao Paulo","startDate":"2014-01","conditions":"Sexuality","enrollment":60},{"nctId":"NCT01654185","phase":"PHASE2","title":"Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Xichun Hu","startDate":"2012-07","conditions":"Metastatic Breast Cancer","enrollment":60},{"nctId":"NCT01626222","phase":"PHASE3","title":"4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06","conditions":"Metastatic Breast Cancer","enrollment":301},{"nctId":"NCT02404051","phase":"PHASE3","title":"Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2015-12","conditions":"Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Tumor","enrollment":745},{"nctId":"NCT00933309","phase":"PHASE1","title":"The Impact of Obesity and Obesity Treatments on Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-07","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT01202591","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-12","conditions":"FGFR Inhibition, Pharmacokinetics, Biomarkers, ER+ Breast Cancer","enrollment":127},{"nctId":"NCT01004081","phase":"PHASE2","title":"Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-11","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT00038467","phase":"PHASE3","title":"Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"1998-02","conditions":"Breast Neoplasms","enrollment":4740},{"nctId":"NCT02025712","phase":"PHASE2","title":"Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Organisation for Oncology and Translational Research","startDate":"","conditions":"Hormone Receptor Positive Malignant Neoplasm of Breast","enrollment":35},{"nctId":"NCT01965080","phase":"PHASE2","title":"Exemestane in Advanced and Recurrent Endometrial Carcinoma","status":"COMPLETED","sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","startDate":"2004-03","conditions":"Endometrial Cancer","enrollment":52},{"nctId":"NCT00767520","phase":"PHASE2","title":"Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-02","conditions":"Breast Cancer","enrollment":155},{"nctId":"NCT00793546","phase":"PHASE2","title":"Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-02","conditions":"Advanced Breast Cancer","enrollment":42},{"nctId":"NCT01239745","phase":"","title":"Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-04","conditions":"Breast Neoplasms","enrollment":46},{"nctId":"NCT01155063","phase":"","title":"Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Early Breast Cancer","enrollment":89},{"nctId":"NCT00935558","phase":"PHASE2","title":"Dendritic Cell Based Therapy for Breast Cancer Patients","status":"WITHDRAWN","sponsor":"Inge Marie Svane","startDate":"2009-07","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00143390","phase":"PHASE3","title":"Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-04","conditions":"Breast Neoplasms","enrollment":298},{"nctId":"NCT00279448","phase":"PHASE3","title":"Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-01","conditions":"Breast Neoplasms","enrollment":9779},{"nctId":"NCT00944918","phase":"PHASE3","title":"Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-12","conditions":"Progression-free Survival","enrollment":25},{"nctId":"NCT00525096","phase":"PHASE3","title":"Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2003-07","conditions":"Metastatic Breast Cancer","enrollment":157},{"nctId":"NCT01237327","phase":"PHASE3","title":"Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-11","conditions":"Metastatic Breast Cancer","enrollment":84},{"nctId":"NCT01050634","phase":"","title":"Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-11","conditions":"Post Menopausal Women With Early Breast Cancer","enrollment":980},{"nctId":"NCT00932165","phase":"","title":"Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-12","conditions":"Breast Neoplasms","enrollment":451},{"nctId":"NCT00038103","phase":"PHASE2","title":"Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-01","conditions":"Breast Neoplasms","enrollment":111},{"nctId":"NCT00919399","phase":"PHASE2","title":"Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2002-01","conditions":"Breast Neoplasms","enrollment":15},{"nctId":"NCT00649090","phase":"PHASE4","title":"A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-03","conditions":"Breast Neoplasms","enrollment":1549}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Exemestane Tablets","genericName":"Exemestane Tablets","companyName":"Tolmar Inc.","companyId":"tolmar-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Exemestane is a steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer. Used for Hormone receptor-positive breast cancer in postmenopausal women (adjuvant and extended therapy), Advanced or metastatic breast cancer in postmenopausal women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}